Association between interleukin-6 -174G/C polymorphism and the risk of Alzheimer's disease: A meta-analysis

International Journal of Neuroscience

Volumn 123, Issue 9, 2013, Pages 626-635

  Hua, Ye ^a   Guo, Xuedan ^a   Huang, Qing ^b   Kong, Yuenan ^a   Lu, Xiaojie ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Gene polymorphism; Interleukin 6; Meta analysis

Indexed keywords

INTERLEUKIN 6;

ALLELE; ALZHEIMER DISEASE; ARTICLE; DNA POLYMORPHISM; GENETIC ASSOCIATION; GENOTYPE; HUMAN;

ALZHEIMER DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DATABASES, BIBLIOGRAPHIC; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84882436628     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2013.784286     Document Type: Article

References (45)

1. Wenk GL. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 2003;64:7-10
2. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421
3. Swardfager W, Lanctot K, Rothenburg L, et al. A meta analysis of cytokines in Alzheimer's disease. Biol Psychiatry 2010;68(10):930-41
4. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005;37:289-305
5. Di Bona D, Plaia A, Vasto S, et al. Association between the interleukin-1beta polymorphisms and Alzheimer's disease: A systematic review and meta-Analysis. Brain Res Rev 2008;59:155-63
6. Wang M, Jia J. The interleukin-6 gene -572C/G promoter polymorphism modifies Alzheimer's risk in APOE epsilon 4 carriers. Neurosci Lett 2010;482:260-3
7. Di Bona D, Candore G, Franceschi C, et al. Systematic review by meta-Analyses on the possible role of TNF-Alpha polymorphisms in association with Alzheimer's disease. Brain Res Rev 2009;61:60-8
8. Cousin E, Maće S, Rocher C, et al. No replication of genetic association between candidate polymorphisms and Alzheimer's disease. Neurobiol Aging 2011;32(8):1443-51
9. Papassotiropoulos A, Hock C, Nitsch RM. Genetics of interleukin 6: Implications for Alzheimer's disease. Neurobio Aging 2001;22:863-71
10. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6)gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102: 1369-76
11. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997;315:629-34
12. Arosio B, Trabattoni D, Galimberti L, et al. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol Aging 2004;25:1009-15
13. Bagli M, Papassotiropoulos A, Knapp M, et al. Association between an interleukin-6 promoter and 30 flanking region haplotype and reduced Alzheimer's disease risk in a German population. Neurosci Lett 2000;283:109-12
14. Bhojak TJ, DeKosky ST, Ganguli M, Kamboh MI. Genetic polymorphisms in the cathepsin D and interleukin-6 genes and the risk of Alzheimer's disease. Neurosci Lett 2000;288:21-4
15. Capurso C, Solfrizzi V, Colacicco AM, et al. Interleukin 6-174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:177-82
16. Combarros O, Warden DR, Hammond N, et al. The dopamine beta-hydroxylase-1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project, BMC Med Genet 2010;11:162
17. Depboylu C, Lohmuller F, Gocke P, et al. An interleukin-6 promoter variant is not associated with an increased risk for Alzheimer's disease. Dement Geriatr Cogn Disord 2004;17:170-3
18. Faltraco F, Burger K, Zill P, et al. Interleukin-6 -174 G/C promoter gene polymorphism C allele reduces Alzheimer's disease risk. J Am Geriatr Soc 2003;51:578-9
19. Klimkowicz-Mrowiec A, Wolkow P, Spisak K, et al. Interleukin-6 gene -174 C/G and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population. Neurol Neurochir Pol 2010;44:537-41
20. Koivisto AM, Helisalmi S, Pihlajamaki J, et al. Interleukin-6 promoter polymorphism and late-onset Alzheimer's disease in the Finnish population. J Neurogenet 2005;19:155-61
21. Licastro F, Grimaldi LM, Bonafe M, et al. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 2003;24:921-6
22. Paradowski B, Celczynska D, Dodosz T, Noga L. Polymorphism 174 G/C of interleukin 6 gene in Alzheimer's disease -preliminary report. Neurol Neurochir Pol 2008;42:312-15
23. Pola R, Flex A, Gaetani E, et al. The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with Alzheimer's disease in an Italian population. Neuroreport 2002;13:1645-7
24. Shawkatova I, Javor J, Parnicka Z, et al. No association between cytokine gene polymorphism and risk of Alzheimer's disease in Slovaks. Acta Neurobiol Exp 2010;70:303-7
25. Vural P, Degirmencioglu S, Parildar-Karpuzoglu H, et al. The combinations of TNF alpha-308 and IL-6 -174 or IL-10-1082 genes polymorphisms suggest an association with susceptibility to sporadic late-onset Alzheimer's disease. Acta Neurol Scand 2009; 120:396-401
26. Zhang Y, Hayes A, Pritchard A, et al. Interleukin-6 promoter polymorphism: Risk and pathology of Alzheimer's disease. Neurosci Lett 2004;362:99-102
27. He MX, Yang WL, Zhang MM, et al. Association between interleukin-6 gene promoter -572C/G polymorphism and the risk of sporadic Alzheimer's disease. Neurol Sci 2010;31(2):165-8
28. Mansoori N, Tripathi M, Alam R, et al. IL-6 -174 G/C and ApoE gene polymorphisms in Alzheimer's and vascular dementia patients attending the cognitive disorder clinic of the All India Institute of Medical Sciences, New Delhi. Dement Geriatr Cogn Disord 2010;30:461-8
29. Nishimura M, Sakamoto T, Kaji R, Kawakami H. Influence of polymorphisms in the genes for cytokines and glutathione S-Transferase omega on sporadic Alzheimer's disease. Neurosci Lett 2004;368(2):140-3
30. Shibata N, Ohnuma T, Takahashi T, et al. Effect of IL-6 polymorphism on risk of Alzheimer disease: Genotype-phenotype association study in Japanese cases. Am J Med Genet 2002;114:436-9
31. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997:48(3):626-32
32. Gruol DL, Nelson TE. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 1997;15:307-39
33. Campbell IL, Stalder AK, Chiang CS, et al. Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol Psychiatry 1997;2:125-9
34. Braida D, Sacerdote P, Panerai AE, et al. Cognitive function in young and adult IL (interleukin)-6 deficient mice. Behav Brain Res 2004;153:423-9
35. McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990;335: 1037
36. Kalman J, Juhasz A, Laird G, et al. Serum interleukin-6 levels correlate with the severity of dementia in Down syndrome and in Alzheimer's disease, Acta Neurol Scand 1997;96:236-40
37. Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-Antichymotrypsin in patients with Alzheimer's disease: Peripheral inflammation or signals from the braiñJ Neuroimmunol 2000; 103:97-102
38. Infante J, Sanz C, Fernandez-Luna JL, et al. Gene-gene interaction between interleukin-6 and interleukin-10 reduces AD risk. Neurology 2004;63:1135-6
39. Dai LM, Liu D, Guo H, et al. Association between polymorphism in the promoter region of interleukin 6 (-174 G/C) and risk of Alzheimer's disease: A meta-Analysis. J Neurol 2012;259:414-9
40. Han XM, Wang CH, Sima XT, Liu SY. Interleukin-6 -174G/C polymorphism and the risk of Alzheimer's disease in Caucasians: A meta-Analysis. Neurosci Lett 2011;504:4-8
41. Khachaturian AS, Corcoran CD, Mayer LS, et al. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County study. Arch Gen Psychiatry 2004;61:518-24
42. Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: A nonlinear model. Neurology 2005;65:1888-93
43. Du Y, Dodel RC, Eastwood BJ, et al. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology 2000;55:480-3
44. Green EK, Harris JM, Lemmon H, et al. Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD?. Neurology 2002;58:1566-8
45. Clarimon J, Bertranpetit J, Calafell F, et al. Joint analysis of candidate genes related to Alzheimer's disease in a Spanish population. Psychiatr Genet 2003;13:85-90